Suppr超能文献

[化疗药物、结直肠癌治疗中的缓解率及耐药机制]

[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].

作者信息

Tegze Bálint, Tulassay Zsolt, Gyôrffy Balázs

机构信息

II. sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary.

出版信息

Magy Onkol. 2006;50(4):315-23. Epub 2007 Jan 10.

Abstract

Colorectal carcinoma is one of the most common cancers in Hungary, responsible for about 5000 deaths each year. In the first line treatment the most commonly used drugs are 5-fluorouracil, oxaliplatin and irinotecan. The most frequently used drug is 5-fluorouracil, which has no effect in 90% of the cases. In combination with leukovorin or with 5-ethyl-2'-deoxyuridin fluorouracil has an increased effect. The main mechanisms of the resistance against 5-fluorouracil are due to the overexpression of dihydropyrimidine dehydrogenase, MRP8, thymidylate synthase, and NFkB p65. Oxaliplatin forms reactive platinum complexes, which are believed to inhibit DNA synthesis by forming interstrand and intrastrand cross-linking of DNA molecules. The oxaliplatin-5-fluorouracil-leucovorin combination was the first to reach more than 20 months median survival. The main mechanisms of resistance are decreased accumulation, increased detoxification and increased DNA repair. Irinotecan inhibits the topoisomerase I enzyme, resulting in the inhibition of the repair of DNA breaks occurring during DNA synthesis. With sequential 5-fluorouracil, oxaliplatin, irinotecan combination 26 months median survival was reached. Mechanisms resulting in resistance are decreased accumulation, increased enzymatic detoxification, alterations of ABC transporters, DNA repair system, apoptotic pathways and topoisomerase I. Survival can be elongated using biological therapy (cetuximab, bevacizumab). In the near future biological therapy is expected to spread.

摘要

结直肠癌是匈牙利最常见的癌症之一,每年导致约5000人死亡。一线治疗中最常用的药物是5-氟尿嘧啶、奥沙利铂和伊立替康。最常用的药物是5-氟尿嘧啶,其在90%的病例中无效。与亚叶酸或5-乙基-2'-脱氧尿苷联合使用时,氟尿嘧啶的效果会增强。对5-氟尿嘧啶耐药的主要机制是二氢嘧啶脱氢酶、MRP8、胸苷酸合酶和NFkB p65的过表达。奥沙利铂形成活性铂配合物,据信通过形成DNA分子的链间和链内交联来抑制DNA合成。奥沙利铂-5-氟尿嘧啶-亚叶酸联合方案是首个使中位生存期超过20个月的方案。耐药的主要机制是蓄积减少、解毒增加和DNA修复增加。伊立替康抑制拓扑异构酶I,导致DNA合成过程中发生的DNA断裂修复受到抑制。采用5-氟尿嘧啶、奥沙利铂、伊立替康序贯联合方案,中位生存期达到了26个月。导致耐药的机制包括蓄积减少、酶解毒增加、ABC转运蛋白改变、DNA修复系统、凋亡途径和拓扑异构酶I改变。使用生物疗法(西妥昔单抗、贝伐单抗)可延长生存期。在不久的将来,生物疗法有望得到推广。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验